Sillajen said Monday that it has presented a poster on the clinical study of BAL0891, an anticancer drug undergoing phase I clinical trials in the U.S. and Korea, at the 2023 EORTC-NCI-AACR Symposium, which opened in Boston, Mass.

The EORTC-NCI-AACR Symposium is an international conference jointly organized by the European Organization for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), which travels annually between Europe and the U.S.

The symposium was held from last Wednesday to Sunday (local time), and the clinical study overview of BAL0891 was released on Saturday.

BAL0891 is a Mitotic Checkpoint Inhibitor-family anticancer drug that Sillajen licensed from Basilea, Switzerland, in September last year. It is a dual kinase inhibitor that hinders two phosphorylation enzymes -- threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1).

The poster introduced BAL0891's mechanism of action, preclinical results, and an overview of ongoing clinical trials in the U.S. and Korea. BAL0891 began enrolling patients with metastatic solid tumors in the U.S. in February. It began enrollment in July in Korea.

"A world-renowned conference has adopted and presented a research overview of a drug that has now begun clinical trials, meaning that the value of the drug and the expectations for the research are great," a Sillajen official said.